Capmatinib
Back to searchMolecule Structure
Scientific Name
Capmatinib
Description of the Drug
Capmatinib is a kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11791
http://www.drugbank.ca/drugs/DB11791
Brand Name(s)
Not Available
Company Owner(s)
Novartis Pharmaceutical Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Hepatocyte growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL3717 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL1426819 | |
Human Metabolome Database | HMDB0249595 | |
DrugBank | DB11791 | |
PubChem: Thomson Pharma | 56473134 | |
PubChem | 25145656 | |
Nikkaji | J3.320.942H | |
BindingDB | 50146167 | |
EPA CompTox Dashboard | DTXSID90145595 | |
DrugCentral | 5392 | |
Brenda | 215759 | |
ChemicalBook | CB92574678 | |
Guide to Pharmacology | 7904 | |
rxnorm | CAPMATINIB HYDROCHLORIDE | CAPMATINIB |
ZINC | ZINC000043195321 |